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Looking for the Target Cell of Kaposi’s 
Sarcoma-Associated Herpesvirus
Nicolas Dupin1 and Philippe A. Grange1
The level of Kaposi’s sarcoma-associated herpesvirus (KSHV) cellular viremia in 
patients with Kaposi’s sarcoma could be related to both the tumor burden and 
its progression. The origin of the spindle cell, the hallmark cell of Kaposi’s sar-
coma, is still debated. Two hypotheses may be formulated, favoring a lymphatic 
endothelial cell or an endothelial-cell precursor evolving into a lymphatic phe-
notype, both preferentially targeted by KSHV.
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Kaposi’s sarcoma (KS) is an oppor-
tunistic tumor that occurs in HIV-
infected patients (AIDS-KS) and in 
the setting of solid-organ transplan-
tation (iatrogenic KS) (Boshoff and 
Weiss, 2002). KS is also reported in 
patients of Mediterranean origin (clas-
sic KS) and sub-Saharan African ori-
gin (endemic KS), without any major 
immune impairment clearly identified. 
Kaposi’s sarcoma-associated herpes-
virus (KSHV) is a gammaherpesvirus 
that was discovered in a patient with 
AIDS-KS and was also named human 
herpesvirus 8. Using PCR techniques, 
several groups have detected KSHV 
in the vast majority of KS tumors, and 
it has been shown to be associated 
with all epidemiologic forms of KS 
(Chang et al., 1994; Boshoff and 
Weiss, 2002).
Morphologic studies based on 
immunohistochemistry or electron 
microscopy have shown that most 
of the cells in KS lesions are latently 
infected, although a small proportion 
of the cells of unknown origin may 
contain replicative virus that may have 
a key role in local tumor progression 
(Orenstein et al., 1997; Grundhoff and 
Ganem, 2004). The presence of KSHV 
DNA in the blood of AIDS–KS patients 
has been reported in more than 50% 
of cases (Whitby et al., 1995). More 
interestingly, it has been shown that 
KSHV cellular viremia is associated 
with both the development and the 
progression of KS in HIV-infected indi-
viduals (Whitby et al., 1995). These 
results suggest that the detection of 
KSHV in blood could predict the evo-
lution of KS in the setting of HIV infec-
tion. KSHV is also associated with the 
multicentric form of Castleman’s dis-
ease, a rare lymphoproliferative disor-
der that is associated with an excess 
risk of KS, as nearly 75% of AIDS 
patients with Castleman’s disease have 
KS. KSHV viremia is clearly associat-
ed with clinical activity in the setting 
of Castleman’s disease, and, unlike 
in KS, 10%–15% of the cells support 
lytic infection in Castleman’s disease 
tumors (Oksenhendler et al., 2000).
The value of measuring KSHV vire-
mia has also been reported in patients 
with iatrogenic KS, but not in patients 
without any apparent immune impair-
ment, such as patients with classic or 
endemic KS. In this issue, the group 
led by Céleste Lebbé adds important 
insights on the value of KSHV viremia 
in both classic KS and endemic KS 
(Pellet et al., 2006). The study involved 
70 patients with classic KS and 11 
patients with endemic KS. Using quan-
titative PCR, the authors confirmed 
that KSHV cellular viremia reflects 
tumor burden and demonstrated that 
it can be correlated to tumor progres-
sion. These findings suggest that it may 
be useful to monitor KSHV cellular 
viremia in patients with KS but without 
HIV infection, such as patients with 
classic or endemic KS.
KSHV may be detected in blood, 
but there are few data on the status of 
the virus in peripheral blood mono-
nuclear cells. One study showed that 
the virus may replicate in peripheral 
blood mononuclear cells while it is 
latent in KS lesions (Decker et al., 
1996). Therefore, given the correla-
tion between tumor progression and 
KSHV cellular viremia, it could be 
suggested that antiherpetic drugs such 
as cidofovir, which have been shown 
to decrease KSHV replication in vitro, 
may impede KS progression (Kedes 
and Ganem, 1997). However, the only 
study evaluating cidofovir activity in 
patients with KS showed no improve-
ment at all (Little et al., 2003). What 
kind of information, then, can we 
expect to gain from cellular viremia in 
the setting of KS? 
(1)  Estimation of tumor activity and 
tumor extent;
(2)  Improved accuracy of prognosis, 
which could assist in therapeutic 
decision making;
(3)  Measurement of efficacy or fail-
ure after starting a treatment.
Given the low level of cellular vire-
mia, is there a place for monitoring 
of such loads in the management of 
classic and endemic KS in the future? 
Probably, but the low detection level 
of viremia observed in these patients 
must be improved by an increase in the 
sensitivity of detection in order to pre-
cisely assess the correlation between 
KSHV viral load and KS staging and 
progression in patients with classic or 
endemic KS.
The other important point raised by 
Pellet et al. (2006) concerns the nature 
of the cells infected by KSHV in blood. 
Previous reports have demonstrated 
that B lymphocytes are infected pref-
erentially, but there is still controversy 
about infection of T lymphocytes and 
monocytes (Ambroziak et al., 1995). 
In this study, Pellet et al. confirmed 
that B lymphocytes and, to a lesser 
extent, monocytes may be infected, 
and they demonstrated that 50% of 
patients have circulating endothe-
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lial cells infected by KSHV. This very 
important finding is directly linked 
with the pathogenesis of KS. KS is a 
complex angiogenic tumor character-
ized by both the presence of ectatic 
vessels and the proliferation of spin-
dle-shaped cells, which are the hall-
mark cells of this neoplasm. Although 
the origin of the spindle cells is still 
undetermined, it was shown that 
they are a heterogeneous popula-
tion of cells expressing markers for 
smooth muscle cells, macrophages, 
and dendritic cells. However, most of 
the spindle cells in KS lesions express 
endothelial markers, including CD31 
and CD34, and recent studies sug-
gest that spindle cells are probably 
of endothelial origin, although the 
lymphatic or vascular nature of these 
cells is still debated, and some recent 
works suggest that they may be more 
of lymphatic origin. Indeed, when 
KSHV infects microvascular endothe-
lial cells, it may drive the cells to lym-
phatic reprogramming with induction 
of the main lymphatic lineage-specific 
genes, including PROX1, which play a 
major role in lymphatic development 
(Hong et al., 2005). Moreover, one 
study reports that the virion envelope-
associated glycoprotein B can activate 
vascular endothelial growth factor 
receptor-3 on the surface of microvas-
cular endothelial cells and that vascu-
lar endothelial growth factor receptor-
3 expression enhances KSHV infection 
(Zhang et al., 2005). Because spindle 
cells express lymphatic endothelial 
markers such as vascular endothelial 
growth factor receptor-3, lyve-1, and 
podoplanin and are also the main 
cells harboring KSHV in KS lesions, it 
may be hypothesized that lymphatic 
endothelial cells are the favored tar-
gets of infection. This is also illustrat-
ed by the fact that in KS lesions, KSHV 
is not present in resident blood ves-
sels despite the production of KSHV 
virions in such tumors (Dupin et al., 
1999). However, another hypothesis 
that has been addressed is that KSHV 
may infect endothelial-cell precursors 
and drive these cells toward a lym-
phatic endothelial-cell phenotype. 
Because neoangiogenic cells asso-
ciated with malignant tumors may 
express some of the lymphatic mark-
ers, the specificity of these observa-
tions should be interpreted with cau-
tion (Jussila et al., 1998).
Finally, Pellet et al. (2006) demon-
strated the absence of an impairment 
of immune response, as they did not 
find any significant decrease in cir-
culating IFN-γ-producing T cells in 
patients with KS. Moreover, the detec-
tion of IFN-γ-producing T cells was not 
associated with negative KSHV vire-
mia; this suggests that IFN-γ-deficient 
activity is not implicated in the control 
of KSHV production in KSHV-infected 
patients. So why do subjects with no 
specific immunosuppression develop 
KS? It may be due to a KSHV-specific 
immune defect that would allow the 
virus to escape immune-cell con-
trol, as some studies have shown that 
patients with KS lack specific immune 
cellular response, in contrast to KSHV-
infected patients without KS. This 
study suggests that monitoring KSHV 
viremia may be useful in patients 
with classic and endemic KS as long 
as these patients harbor no apparent 
immune impairment. The predictive 
value of KSHV detection in blood for 
KS development is, however, not clear, 
unlike that of KSHV detection in HIV-
infected patients. Other factors such as 
genotype and specific cellular immune 
dysfunction may be associated with 
KS development and progression in 
patients with non-HIV-related KS.
However, many questions about 
the origin of KSHV-infected circu-
lating endothelial cells still arise 
(Figure 1). Do these cells come from 
KS lesions recirculating in blood? Or 
do they originate from medullar pre-
cursors and thereafter seed in the 
skin and promote development of 
KS? Why do patients with KS have an 
increased number of circulating endo-
thelial cells? Cause or consequence of 
KS lesion: The question is still unan-
swered and deserves to be explored 
by further studies. What is the next 
step? Probably to demonstrate that the 
circulating endothelial cells infected 
by KSHV and the spindle cells found 
in KS tumors share common features 
— especially the lymphatic markers, 
as spindle cells may be derived from 
lymphatic endothelial precursors.
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Figure 1. Hypothesis of KSHV-infected circulating endothelial cells in Kaposi’s sarcoma 
development. (1) Blood compartment with Kaposi’s sarcoma-associated herpesvirus (KSHV)-infected 
circulating endothelial cells (brown diamonds). (2) Infected circulating endothelial cells may seed 
in the skin (this property may be acquired secondary to KSHV infection). (3) Infected circulating 
endothelial cells may interfere with lymphatic endothelium cells (blue ovals). The resulting mixed 
population of infected and uninfected cells may participate in the formation of ectatic vessels 
(initial stage of Kaposi’s sarcoma). (4) KSHV may confer a growth advantage to infected cells, 
promoting their expansion (nodular stage of Kaposi’s sarcoma). (5) Infected cells may shed into the 
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Café-au-lait Patches and Senile 
Plaques: How APPt the Connection?
Ganesh Diwakar1 and Thomas J. Hornyak1
Neurofibromatosis type 1 (NF1) is a genetic disease caused by mutations in the 
NF1 gene, which encodes the protein neurofibromin. Patients exhibit character-
istic hyperpigmented patches called café-au-lait patches. Melanocytes of NF1 
patients differ from normal human melanocytes, but no differences account 
completely for lesional hyperpigmentation. An association between β-amyloid 
precursor protein (APP) and neurofibromin, and their localization to the mela-
nosome, may help explain the development of café-au-lait patches.
Journal of Investigative Dermatology (2006) 126, 547–550. doi:10.1038/sj.jid.5700165
The nature of café-au-lait lesions in 
neurofibromatosis type 1 (NF1) has 
interested investigators for decades. 
NF1 is an autosomal dominant genetic 
disease characterized by a number of 
different abnormalities affecting vari-
ous organ systems and tissues in addi-
tion to the characteristic hyperpig-
mented — or café-au-lait, as they will 
be referred to here — macules and 
patches. These abnormalities include 
benign neoplasms such as dermal neu-
rofibromas and optic gliomas, as well 
as a predisposition to malignancies 
such as pheochromocytomas and juve-
nile myeloid leukemia. NF1 is associ-
ated with mutations in the human NF1 
gene. NF1 encodes the protein neuro-
fibromin, a large, 260-kilodalton tumor 
suppressor protein containing a Ras–
GTPase-activating protein (RasGAP) 
domain. Perhaps the best-understood 
biochemical function of neurofibromin 
is its activity as a negative regulator of 
Ras, accelerating the conversion of 
active, guanosine triphosphate-bound 
Ras to inactive, guanosine diphos-
phate-bound Ras (DeClue et al., 1992). 
The cellular abnormalities that result 
in various clinical manifestations of 
NF1 have been attributed to hyperac-
tive Ras activity due to loss-of-function 
mutations or deletions of one or both 
NF1 alleles.
Early studies of café-au-lait patches 
focused on characterizing their den-
sity and morphology and revealed 
two surprising observations: (1) not 
only did the café-au-lait patch often 
have a somewhat higher number of 
melanocytes than the normal skin of 
historical controls, but so did the rest 
of the skin in these patients; and (2) 
virtually all of the melanocytes visual-
ized in the epidermis of NF1 patients, 
whether lesional or non-lesional, 
contained enlarged pigment granules 
(Benedict et al., 1968; Martuza et al., 
1985). Both melanocyte and kerati-
nocyte numbers were quantified in 
lesional and non-lesional skin of NF1 
patients as well as the skin of normal 
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